Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome

Cancer

Volumn 117, Issue 7, 2011, Pages 1463-1469

  Bello, Celeste ^a   Yu, Daohai ^a   Komrokji, Rami S ^a   Zhu, Weiwei ^a   Wetzstein, Gene A ^a   List, Alan F ^a   Lancet, Jeffrey E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

acute; azacitidine; cytogenetics; decitabine; lenalidomide; leukemia; methylation; myelodysplastic syndromes; myelodysplastic myeloproliferative diseases; myeloid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; AGED; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; CYTOGENETICS; DISEASE DURATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 79952832445     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25598     Document Type: Article

References (23)

1. Lowenberg B, Downing JR, Burnett A., Acute myeloid leukemia. N Engl J Med. 1999; 341: 1051-1062. (Pubitemid 29451802)
2. Surveillance, Epidemiology, and End Results Program. Acute Myeloid Leukemia Incidence for 2000-2004. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2007. Available at: www.seer.cancer.gov Accessed November 2009.
3. Litzow MR., The therapy of relapsed acute leukaemia in adults. Blood Rev. 2004; 18: 39-63. (Pubitemid 38200500)
4. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107: 3481-3485.
5. Kantarjian H, O Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006; 106: 1090-1098.
6. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood. 1998; 92: 2322-2333. (Pubitemid 28452973)
7. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 1312-1320.
8. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000; 96: 4075-4083.
9. Lancet JE, Willman CL, Bennett JM., Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol Clin North Am. 2000; 14: 251-267. (Pubitemid 30078441)
10. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 1268-1274. (Pubitemid 19220128)
11. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995; 86: 457-462.
12. Kantarjian HM, O′Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007; 109: 265-273. (Pubitemid 46106241)
13. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20: 2429-2440. (Pubitemid 34525728)
14. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465. (Pubitemid 44511560)
15. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981; 58: 1203-1212. (Pubitemid 12251149)
16. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
17. Byrd JJC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336. (Pubitemid 35429670)
18. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 3671-3674.
19. Qin T, Jelinek J, Si J, Shu J, Issa JP., Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood. 2009; 113: 659-667.
20. List AF., Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996; 10: 937-942. (Pubitemid 26235923)
21. Desiderato L, Davey MW, Piper AA., Demethylation of the human MDR1 5-region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet. 1997; 23: 391-400. (Pubitemid 127726627)
22. Kusaba H, Nakayama M, Harada T, et al. Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer. Somat Cell Mol Genet. 1997; 23: 259-274. (Pubitemid 28162721)
23. Kantharidis P, El-Osta A, deSilva M, et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res. 1997; 3: 2025-2032. (Pubitemid 27505129)